Drug Profile
ZSP 1601
Alternative Names: ZSP-1601Latest Information Update: 20 Jun 2023
Price :
$50
*
At a glance
- Originator Guangdong Zhongsheng Pharmaceutical
- Developer Guangdong Raynovent Biotech; Guangdong Zhongsheng Pharmaceutical
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Type 2 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 03 Jun 2023 Phase-II clinical trials in Non-alcoholic steatohepatitis in China (PO) (NCT05692492)
- 20 Jan 2023 Guangdong Raynovent Biotech plans a phase II trial for Non-alcoholic steatohepatitis (In adults, In the elderly) in China (PO, Tablet) in February 2023(NCT05692492)
- 22 Jun 2022 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Non-alcoholic steatohepatitis presented at the International Liver Congress 2022 (ILC-2022)